Skip to main content

Advanced dosimetry for novel radiotherapy approaches in brain tumors (DOSE BRAIN)

PLEC2022-009476

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i en Líneas Estratégicas
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Evaluation of the two-voltage method for parallel-plate ionization chambers irradiated with pulsed beams

  • Paz-Martín, José
  • Schüller, Andreas
  • Bourgouin, Alexandra
  • Gago-Arias, Araceli
  • González-Castaño, Diego M,
  • Gómez-Fernández, Nicolás
  • Pardo-Montero, Juan
  • Gómez, Faustino
Air-vented ionization chambers exposed to clinical radiation beams may suffer from recombination during the drift of the charge carriers towards the electrodes. Thus, dosimetry protocols recommend the use of a correction factor, usually denominated saturation factor ( ksat$k_{\rm sat}$ ), to correct the ionization chamber readout for the incomplete collection of charge. The two-voltage method (TVM) is the recommended methodology for the calculation of the saturation factor, however, it is based on the early Boag model, which only takes into account the presence of positive and negative ions in the ionization chamber and does not account for the electric field screening or the free electron contribution to the signal., Jose Paz-Martín has received a predoctoral research contract from the Xunta de Galicia regional govern-ment. Juan Pardo-Montero acknowledges the support of Xunta de Galicia, Axencia Galega de Innovación (grant IN607D2022). This work has been developed under the project 18HLT04 UHDpulse with funding from the EMPIR innovation program. This work has received funding from ‘la Caixa’ Foundation under the grant agreement HR23-00718 (‘Dosimetry monitor for FLASH therapy’ project) and from grant PLEC2022-009476 funded by MCIN/AEI/10.13039/501100011033 and by the ‘European Union NextGenerationEU/PRTR’. The authors thank Christoph Makowski for the electron linear accelerator maintenance during the measurement campaign, Olaf Tappe for the machining work, and Thomas Hackel for the alanine measurements., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Transcriptional repression of SOX2 by p53 in cancer cells regulates cell identity and migration

  • Lado-Fernández, Patricia
  • Vilas, Jéssica M
  • Fernandes, Tânia
  • Carneiro, Carmen
  • Da Silva-Álvarez, Sabela
  • Estévez-Souto, Valentín
  • Pedrosa, Pablo
  • González-Barcia, Miguel
  • Abatti, Luis E
  • Mitchell, Jennifer A
  • Rivas, Carmen
  • Moreno-Bueno, Gema
  • Vidal, Anxo
  • Collado, Manuel
During cancer development and progression, many genetic alterations lead to the acquisition of novel features that confer selective advantage to cancer cells and that resemble developmental programs. SRY-box transcription factor 2 (SOX2) is one of the key pluripotency transcription factors, expressed during embryonic development and active in adult stem cells. In cancer, SOX2 is frequently dysregulated and associated with tumor stemness and poor patient survival. SOX2 expression is suppressed in differentiated cells by tumor suppressor proteins that form a transcriptional repressive complex. We previously identified some of these proteins and found that their absence combined with deficiency in Trp53 leads to maximal dysregulated expression of Sox2. Using cancer cell lines of different origin and with different p53 status, we show here that manipulating TP53 to restore or decrease its activity results in repression or induction of SOX2, respectively. Mechanistically, we observed that the regulation of SOX2 expression by TP53 is transcriptional and identified Trp53 bound to the promoter region and the Sox2 Regulatory Region 2 enhancer of Sox2. Forcing high levels of SOX2 in cancer cells leads to morphological changes that molecularly correspond to the acquisition of a more mesenchymal phenotype, correlating with an increased migratory capacity. Finally, the analysis of human breast cancer samples shows that this correlation between TP53 status, levels of expression of SOX2, and a more metastatic phenotype is also observed in cancer patients. Our results support the notion that lack of TP53 in tumor cells results in deregulated expression of developmental gene SOX2 with phenotypic consequences related to increased malignization., Work in the laboratory of Manuel Collado is funded by grants from MCINN/AEI/FEDER, UE (PID2021-125479OB-I00) and GAIN, Xunta de Galicia (IN607D2021/08 and IN607B2024/13). The laboratory of Anxo Vidal is funded by MCINN/AEI/FEDER, UE (PLEC2022-009476), and Xunta de Galicia (ED431C 2023/10). Patricia Lado-Fernández was supported by a predoctoral fellowship from GAIN, Xunta de Galicia (ED481A-2020/066) and funds from Deputación da Coruña (BINV-CS/2023 #2023000020568); Jéssica M. Vilas and Pablo Pedrosa were supported by predoctoral fellowships from GAIN, Xunta de Galicia (PRE/2012/317 and IN606A-2017/002, respectively); Sabela Da Silva-Álvarez was supported by a postdoctoral fellowship from GAIN (IN606B-2021/011), Xunta de Galicia, and Juan de la Cierva contract Grant (JDC2022-049032-I) funded by MICIU/AEI/10.13039/501100011033 and by European Union NextGenerationEU/PRTR., Peer reviewed